domingo, 26 de agosto de 2012

National Guideline Clearinghouse | Management of varicella infection (chickenpox) in pregnancy.

full-text ►
National Guideline Clearinghouse | Management of varicella infection (chickenpox) in pregnancy.

Guideline Title

Management of varicella infection (chickenpox) in pregnancy.

Bibliographic Source(s)

Shrim A, Koren G, Yudin MH, Farine D. Management of varicella infection (chickenpox) in pregnancy. J Obstet Gynaecol Can 2012 Mar;34(3):287-92. [36 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

J Obstet Gynaecol Can. 2012 Mar;34(3):287-92.

Management of varicella infection (chickenpox) in pregnancy.

Shrim A, Koren G, Yudin MH, Farine D; Maternal Fetal Medicine Committee.

Source

Montreal QC.

Abstract

OBJECTIVE:

To review the existing data regarding varicella zoster virus infection (chickenpox) in pregnancy, interventions to reduce maternal complications and fetal infection, and antepartum and peripartum management.

METHODS:

The maternal and fetal outcomes in varicella zoster infection were reviewed, as well as the benefit of the different treatment modalities in altering maternal and fetal sequelae. Evidence: Medline was searched for articles and clinical guidelines published in English between January 1970 and November 2010.

VALUES:

The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care. Recommendations for practice were ranked according to the method described in that report (Table).

RECOMMENDATIONS:

1. Varicella immunization is recommended for all non-immune women as part of pre-pregnancy and postpartum care. (II-3B) 2. Varicella vaccination should not be administered in pregnancy. However, termination of pregnancy should not be advised because of inadvertent vaccination during pregnancy. (II-3D) 3. The antenatal varicella immunity status of all pregnant women should be documented by history of previous infection, varicella vaccination, or varicella zoster immunoglobulin G serology. (III-C) 4. All non-immune pregnant women should be informed of the risk of varicella infection to themselves and their fetuses. They should be instructed to seek medical help following any contact with a person who may have been contagious. (II-3B) 5. In the case of a possible exposure to varicella in a pregnant woman with unknown immune status, serum testing should be performed. If the serum results are negative or unavailable within 96 hours from exposure, varicella zoster immunoglobulin should be administered. (III-C) 6. Women who develop varicella infection in pregnancy need to be made aware of the potential adverse maternal and fetal sequelae, the risk of transmission to the fetus, and the options available for prenatal diagnosis. (II-3C) 7. Detailed ultrasound and appropriate follow-up is recommended for all women who develop varicella in pregnancy to screen for fetal consequences of infection. (III-B) 8. Women with significant (e.g., pneumonitis) varicella infection in pregnancy should be treated with oral antiviral agents (e.g., acyclovir 800 mg 5 times daily). In cases of progression to varicella pneumonitis, maternal admission to hospital should be seriously considered. Intravenous acyclovir can be considered for severe complications in pregnancy (oral forms have poor bioavailability). The dose is usually 10 to 15 mg/kg of BW or 500 mg/m² IV every 8 h for 5 to 10 days for varicella pneumonitis, and it should be started within 24 to 72 h of the onset of rash. (III-C) 9. Neonatal health care providers should be informed of peripartum varicella exposure in order to optimize early neonatal care with varicella zoster immunoglobulin and immunization. (III-C) Varicella zoster immunoglobulin should be administered to neonates whenever the onset of maternal disease is between 5 days before and 2 days after delivery. (III-C).